Annexon shares surge 11.06% after-hours following EMA marketing authorization application submission for Tanruprubart in Guillain-Barré Syndrome.

Annexon Inc. (ANNX) surged 11.06% in after-hours trading following the announcement that it submitted a marketing authorization application for tanruprubart to the European Medicines Agency (EMA) for Guillain-Barré Syndrome treatment and accelerated its next-generation immunotherapy platform for neuroinflammatory diseases, targeting key regulatory milestones in 2026. The EMA submission, a critical step toward commercialization in Europe, and the platform’s progress signaled advancing clinical and regulatory momentum, bolstering investor confidence. Recent events, including participation in the J.P. Morgan Healthcare Conference and positive analyst ratings, further reinforced the stock’s appeal. These developments align with the company’s focus on expanding its therapeutic pipeline and achieving high-impact milestones, directly supporting the post-market rally.